title: Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201.
abstract: OBJECTIVE
  We previously reported the feasibility of short-term low-volume hydration in patients with advanced lung cancer who received cisplatin-based chemotherapy (Jpn J Clin Oncol 2013). We sought to determine the clinical usefulness of a more convenient hydration method, evaluating the safety and efficacy of shorter-term and lower-volume hydration.
  
  
  METHODS
  Chemonaïve patients with advanced lung cancer who were ≤ 75 years and reserved an adequate renal function for cisplatin use (≥ 60 mg/m(2)) were eligible. An intravenously administered hydration of 1700 ml in ~3.5 h with 1500 ml of orally administered hydration was investigated. The primary endpoint was the proportion of patients without grade 2 or worse renal toxicity in the first cycle.
  
  
  RESULTS
  A total of 45 patients were registered, all of whom were evaluable for renal toxicity. The median baseline creatinine score was 0.70 mg/dl, and the median cisplatin dose on day 1 was 75 mg/m(2). In the first cycle, one patient (2 %) developed grade 2 creatinine toxicity, and thus, the proportion of patients with less than grade 2 was 98 % (the lower limit of 95 % confidence interval; 93 %), which met the primary endpoint. Five patients (11 %) had grade 1 or greater nephrotoxicity, three of whom successfully recovered. The objective response rate was 24 % and median progression-free survival 5.8 months.
  
  
  CONCLUSIONS
  This prospective study demonstrated the safety and efficacy of shorter-term lower-volume hydration.
authors.affiliation: Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
authors.forename: Kiichiro
authors.initials: K
authors.lastname: Ninomiya
authors.affiliation: Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan. khotta@md.okayama-u.ac.jp.|Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan. khotta@md.okayama-u.ac.jp.
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Hotta
authors.affiliation: Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
authors.forename: Akiko
authors.initials: A
authors.lastname: Hisamoto-Sato
authors.affiliation: Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
authors.forename: Eiki
authors.initials: E
authors.lastname: Ichihara
authors.affiliation: Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
authors.forename: Hiroko
authors.initials: H
authors.lastname: Gotoda
authors.affiliation: Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Morichika
authors.affiliation: Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
authors.forename: Tomoki
authors.initials: T
authors.lastname: Tamura
authors.affiliation: Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
authors.forename: Hiroe
authors.initials: H
authors.lastname: Kayatani
authors.affiliation: Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Minami
authors.affiliation: Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
authors.forename: Toshio
authors.initials: T
authors.lastname: Kubo
authors.affiliation: Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Tabata
authors.affiliation: Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
authors.forename: Mitsune
authors.initials: M
authors.lastname: Tanimoto
authors.affiliation: Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Kiura
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced / Q000517:prevention & control*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002945:Cisplatin / Q000008:administration & dosage; D003404:Creatinine / Q000097:blood; D018572:Disease-Free Survival; D005240:Feasibility Studies; D005260:Female; D005440:Fluid Therapy / Q000379:methods*; D006801:Humans; D007564:Japan; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D066066:Response Evaluation Criteria in Solid Tumors
chemical_list: D003404:Creatinine; D002945:Cisplatin
keywords: Cisplatin; Hydration; Lung cancer